Company: ARTL
Filing Date: 2025-10-31
Form Type: 8-K
Source: 0001640334-25-001930
Chunk: 0

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-10-31
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry Into a Material Definitive Agreement.

On October 28, 2025, Artelo Biosciences, Inc. (the “ Company”) entered into a Subscription Agreement (the “ Subscription Agreement”) pursuant to which it issued and sold to certain investors (the “ Investors”), and the Investors purchased (by converting all or a portion of the unconverted “ Voluntary Conversion” portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the “ Notes”) to the Investors in an aggregate principal amount of $690,154.69; and (ii) warrants (the “ Warrants”) to purchase an aggregate of 438,182 shares of the Company’s common stock, par value $0.001 per share (“ Common Stock”), at an exercise price of $3.40 per share (collectively, the “ Offering”). The sale and issuance of the Notes and Warrants closed effective as of October 28, 2025 (the “ Closing Date”). For more information regarding the convertible promissory notes issued to the Investors on May 1, 2025, see Item 1.01 of the Form 8-K filed by the Company on May 1, 2025.

The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Notes). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable six months after the closing of the Notes Offering (the “Maturity Date”).

At any time prior to the Maturity Date, all or any portion of the outstanding principal amount of the Notes, together with the accrued and unpaid interest, shall be convertible, in whole or in part, into shares of Common Stock, at a conversion price of $3.40 (the “Conversion Shares”).

Each Warrant shall be immediately exercisable after issuance for five (5) years. Each Warrant will be exercisable by payment of the exercise price in cash or on a cashless basis if at the time of exercise there is no effective resale registration statement and will contain customary anti-dilution provisions (in the case of stock splits, dividends, recapitalizations, mergers and similar transactions).

A holder of a Note or Warrant may not convert or exercise any such Note